STOCK TITAN

NEUROONE (NASDAQ: NMTC) director granted options and 41,929 RSUs

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

NEUROONE MEDICAL TECHNOLOGIES Corp director Jason Richard Mills reported equity compensation awards. He received options to purchase 26,036 shares of common stock at an exercise price of $0.795 per share, expiring on April 2, 2036, vesting in 12 equal monthly installments.

He also received a grant of 41,929 restricted stock units that vest in 12 equal monthly installments over one year, with vesting at the end of each month. Following the stock grant, he holds 49,687 shares of common stock directly.

Positive

  • None.

Negative

  • None.
Insider Mills Jason Richard
Role Director
Type Security Shares Price Value
Grant/Award Option to Purchase Common Stock 26,036 $0.00 --
Grant/Award Common Stock 41,929 $0.00 --
Holdings After Transaction: Option to Purchase Common Stock — 26,036 shares (Direct); Common Stock — 49,687 shares (Direct)
Footnotes (1)
  1. Represents a grant of restricted stock units, which vest in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. The option vests in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month.
Option grant size 26,036 options Director option award on April 3, 2026
Option exercise price $0.795 per share Exercise price for director options
Option expiration April 2, 2036 Expiration date of granted options
RSU grant size 41,929 RSUs Restricted stock units vesting over one year
Shares held after grant 49,687 shares Common stock directly owned after award
restricted stock units financial
"Represents a grant of restricted stock units, which vest in 12 equal monthly installments"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
exercise price financial
"He received options to purchase 26,036 shares ... at an exercise price of $0.795 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"vest in 12 equal monthly installments over a one-year period, with such vesting to occur"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiring on April 2, 2036, vesting in 12 equal monthly installments"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mills Jason Richard

(Last)(First)(Middle)
7599 ANAGRAM DR

(Street)
EDEN PRAIRIE MINNESOTA 55344

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
NEUROONE MEDICAL TECHNOLOGIES Corp [ NMTC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/03/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/03/2026A41,929(1)A$049,687D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Option to Purchase Common Stock$0.79504/03/2026A26,036 (2)04/02/2036Common Stock26,036$026,036D
Explanation of Responses:
1. Represents a grant of restricted stock units, which vest in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month.
2. The option vests in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month.
/s/ Emily Johns, by Power of Attorney04/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did NMTC director Jason Mills report on this Form 4?

Jason Mills reported equity compensation awards, including stock options and restricted stock units. These are grants from NEUROONE MEDICAL TECHNOLOGIES Corp, not open-market purchases, and reflect standard director compensation rather than discretionary buying or selling in the public market.

How many stock options did Jason Mills receive from NEUROONE MEDICAL TECHNOLOGIES (NMTC)?

Jason Mills received options to purchase 26,036 shares of NEUROONE common stock. These options have an exercise price of $0.795 per share and expire on April 2, 2036, providing long-term equity exposure if he chooses to exercise in the future.

What are the terms of the restricted stock units granted to NMTC director Jason Mills?

Jason Mills was granted 41,929 restricted stock units in NEUROONE MEDICAL TECHNOLOGIES. These RSUs vest in 12 equal monthly installments over one year, with each monthly tranche vesting at the end of the month, aligning his compensation with ongoing board service.

How do the stock options granted to NMTC’s Jason Mills vest over time?

The options granted to Jason Mills vest in 12 equal monthly installments over a one-year period. Vesting occurs at the end of each month, meaning his exercisable option balance increases gradually as each monthly installment becomes vested throughout the year.

How many NEUROONE (NMTC) common shares does Jason Mills hold after these grants?

After the reported grant of common stock, Jason Mills directly holds 49,687 shares of NEUROONE common stock. This figure reflects his updated direct ownership following the award of 41,929 shares, which were reported as a grant/acquisition at no cash purchase price.

Were Jason Mills’ NMTC transactions open-market buys or compensation grants?

The transactions were compensation grants, not open-market trades. Both the options and the 41,929 common shares are coded as acquisitions from grants or awards, with a reported price of $0.0000 per share, consistent with equity-based director compensation.